Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (1081-1090 of 1,298) with videos related to

Pageof 130
Sort By:
Cancers|November 9, 2024
Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic CancerRanish K Patel, Michael Parappilly, Hannah C Farley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancerBryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.
Cancer Research|August 2, 2001
Genetic analysis of early- versus late-stage ovarian tumorsV Shridhar, J Lee, A Pandita, et al.
Cancer Cell|September 10, 2014
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancerXiaowen Hu, Yi Feng, Dongmei Zhang, et al.
Oncogene|July 28, 2015
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancerZ Timsah, Z Ahmed, C Ivan, et al.
Cancer|November 23, 2017
Physician interpretation of genomic test results and treatment selectionLauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Cancer Research|March 18, 2016
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF InhibitorsAnna Budina-Kolomets, Marie R Webster, Julia I-Ju Leu, et al.
Journal of Inherited Metabolic Disease|February 17, 2017
Mild orotic aciduria in UMPS heterozygotes: a metabolic finding without clinical consequencesSaskia B Wortmann, Margaret A Chen, Roberto Colombo, et al.
British Journal of Cancer|October 9, 1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre studyC Chabannon, K Cornetta, J P Lotz, et al.
JCO Precision Oncology|September 14, 2019
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutationsE Ileana Dumbrava, L Brusco, M Daniels, et al.
Pageof 130

Showing results (1081-1090 of 1,298) with videos related to

Sort By:
Pageof 130
Cancers|November 9, 2024
Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic CancerRanish K Patel, Michael Parappilly, Hannah C Farley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancerBryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.
Cancer Research|August 2, 2001
Genetic analysis of early- versus late-stage ovarian tumorsV Shridhar, J Lee, A Pandita, et al.
Cancer Cell|September 10, 2014
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancerXiaowen Hu, Yi Feng, Dongmei Zhang, et al.
Oncogene|July 28, 2015
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancerZ Timsah, Z Ahmed, C Ivan, et al.
Cancer|November 23, 2017
Physician interpretation of genomic test results and treatment selectionLauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Cancer Research|March 18, 2016
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF InhibitorsAnna Budina-Kolomets, Marie R Webster, Julia I-Ju Leu, et al.
Journal of Inherited Metabolic Disease|February 17, 2017
Mild orotic aciduria in UMPS heterozygotes: a metabolic finding without clinical consequencesSaskia B Wortmann, Margaret A Chen, Roberto Colombo, et al.
British Journal of Cancer|October 9, 1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre studyC Chabannon, K Cornetta, J P Lotz, et al.
JCO Precision Oncology|September 14, 2019
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutationsE Ileana Dumbrava, L Brusco, M Daniels, et al.
Pageof 130